Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Urology

Expert Opinion / Commentary · March 11, 2015

Searching for the Optimal BCG Maintenance Regimen

Thomas Guzzo MD, MPH

 

 Save  Recommend
 Share

Additional Info

  1. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized South West Oncology Group study. J. Urol. 2000;163(4):1124-1129.
  2. Pfister C, Kerkeni W, Rigaud J, et al. Efficacy and Tolerance of One-Third Full Dose Bacillus Calmette-Guérin Maintenance Therapy Every 3 Months or 6 Months:Two-Year Results of URO-BCG-4 Multicenter Study. Int J Urol. 2015;22(1):53-60.
  3. Sylvester RJ, Van Der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002;168(5):1964-1970.
  4. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guerin in intermediate and High risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462-472.

Disclosure statements are available on the authors' profiles:

Thomas Guzzo MD, MPH

Further Reading

Recently Updated